IGF2 and colorectal carcinoma: Thus, our findings demonstrate that aberrant IGF2 hypermethylation can be assayed with a blood-based test and that the PBL IGF2 methylation status is likely to be a valuable predictive biomarker for CRC risk, independent of LOI of IGF2.